EGFR and lung cancer: Real‐world health utility scores (HUS) in epidermal growth factor receptor mutations (EGFRm) non‐small cell lung cancer outpatients were similar between those treated by first‐ and second‐line tyrosine kinase inhibitors, which were superior to chemotherapy.